Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2014 · 10-Q
Revenue$4.14M$4.14M+52.3% vs Q3 2013 Net Income-$659.65K-$659.65KN/M vs Q3 2013 EPS Diluted-$0.02-$0.02N/M vs Q3 2013 Gross Profit$1,522,946+103.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$386,514N/M Free Cash Flowderived-$416,572N/M Margins · derivedGross margin36.8%+9.2 pt vs Q3 2013
Operating margin-15.6%+30.0 pt vs Q3 2013
Net margin-15.9%+30.1 pt vs Q3 2013
ended Sep 27, 2014 · filed Nov 6, 2014 · 40 d after period end